Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_assertion type Assertion NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_head.
- NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_assertion description "[Cancer cells require nutrients and energy to adapt to increased biosynthetic activity, and protein synthesis inhibition downstream of mammalian target of rapamycin complex 1 (mTORC1) has shown promise as a possible therapy for acute myeloid leukemia (AML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_provenance.
- NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_assertion evidence source_evidence_literature NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_provenance.
- NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_assertion SIO_000772 24014241 NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_provenance.
- NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_assertion wasDerivedFrom befree-20140225 NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_provenance.
- NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_assertion wasGeneratedBy ECO_0000203 NP504948.RAxKdf_SY8cA23OY1CTmlH3R4l2_OqnzU__yGbSlz1vKI130_provenance.